亚太药业(002370) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥80,720,398.86, representing an increase of 11.13% compared to the same period last year[4] - The net profit attributable to shareholders was -¥18,506,137.10, a decrease of 37.17% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥24,343,761.60, a decrease of 13.14% compared to the previous year[4] - The basic earnings per share for Q3 2023 was -¥0.0328, a decline of 40.26% year-on-year[4] - The company reported a net profit for Q3 2023 of ¥1,260,384.91, a significant recovery from a net loss of ¥81,384,660.92 in the previous year[19] - The company reported a gross profit margin of approximately -17.5% for Q3 2023, compared to -35.8% in the same quarter last year[18] - Basic and diluted earnings per share for Q3 2023 were ¥0.0023, recovering from a loss of ¥0.1517 per share in the same quarter last year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,416,331,465.13, down 7.04% from the end of the previous year[4] - As of September 30, 2023, total assets amounted to CNY 1,416,331,465.13, a decrease from CNY 1,523,620,705.13 at the beginning of the year[15] - Current assets decreased to CNY 928,208,702.98 from CNY 1,004,845,189.33 at the start of the year, with cash and cash equivalents at CNY 705,494,767.43[15] - Non-current assets totaled CNY 488,122,762.15, down from CNY 518,775,515.80 at the beginning of the year[15] - The total liabilities decreased to ¥1,003,206,322.27 from ¥1,222,400,365.02, representing a reduction of 17.9%[18] - The company’s total equity attributable to shareholders increased by 37.15% to ¥413,125,142.86 compared to the end of the previous year[4] Cash Flow - The cash flow from operating activities showed a net outflow of -¥24,816,449.96, an improvement of 44.55% compared to the same period last year[10] - The cash inflow from operating activities for the current period was CNY 187,096,298.37, an increase from CNY 146,702,567.50 in the previous period, representing a growth of approximately 27.5%[20] - The net cash flow from operating activities was -CNY 24,816,449.96, an improvement compared to -CNY 44,754,437.47 in the same period last year[20] - The cash inflow from investment activities was CNY 7,220,218.16, up from CNY 4,663,713.89 in the previous period, indicating a growth of approximately 55.5%[21] - The net cash flow from investment activities was CNY 2,876,915.08, a significant recovery from -CNY 1,128,966.51 in the previous year[21] - The cash inflow from financing activities totaled CNY 50,000,000.00, down from CNY 80,000,000.00 in the previous period, reflecting a decrease of 37.5%[21] - The net cash flow from financing activities was -CNY 16,004,922.79, an improvement from -CNY 42,774,318.25 in the same period last year[21] Shareholder Information - The company converted 1,168,420 "YaYao Convertible Bonds" into 27,752,871 shares during the period, with a total of 1,199,490 bonds converted to date, representing 5.21% of the total shares before conversion[14] - The remaining balance of convertible bonds is CNY 845,051,000, which is 87.57% of the total issued amount[14] - The top shareholder, Ningbo Fubang Holdings, holds 13.67% of the shares, totaling 77,150,000 shares[13] - The company has a total of 10 major shareholders, with the top three holding a combined 19.36% of the shares[13] Operational Highlights - The company reported a significant decrease in accounts receivable financing by 65.10% to ¥9,280,796.70 due to a reduction in bank acceptance bills[7] - Accounts receivable increased to CNY 102,782,322.69 from CNY 89,058,890.84, indicating improved collection efforts[15] - The company reported a decrease in inventory from CNY 95,204,848.03 to CNY 74,377,775.46, reflecting better inventory management[15] - Research and development expenses increased to ¥15,897,936.95, up from ¥12,968,921.21, indicating a year-over-year growth of 22.3%[18] - The company has no new product launches or significant market expansion strategies mentioned in the report[15] Operating Results - Total operating revenue for Q3 2023 reached ¥301,858,122.44, an increase of 28.9% compared to ¥234,144,248.88 in the same period last year[18] - Total operating costs amounted to ¥353,686,573.69, up from ¥299,348,794.05, reflecting a year-over-year increase of 18.2%[18] - The company achieved an operating profit of ¥-49,291,975.33, an improvement from the operating loss of ¥-84,038,989.55 in the previous year[19]